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The Promise and Peril of Embryonic Stem Cell Research:
A Call for Vigilant Oversight
Senator Bill Frist, M.D.*
Embryonic stem cell research raises issues that are fundamentally
different from those affecting other areas of medical research. For the first
time in history, we are faced with research that may profoundly affect the
course of human life and disease by allowing us to more deeply understand
and manipulate the basic building blocks of life itself. Although this
research may produce powerful cures, it also holds great potential for
unintended and even adverse outcomes.
Similar moral and ethical issues have challenged other areas of
research, but the dilemmas posed by embryonic stem cell research are
among the most challenging. It is an issue that cannot be left only to
scientists, or ethicists, or patients, or religious leaders, as it is one that
compels us to balance moral, ethical, scientific, and religious
considerations. It is, therefore, vitally important that we are aware of the
depth of the scientific, ethical, and moral issues involved.
In recent years, Congress has demonstrated a strong, bipartisan
commitment to furthering biomedical research. But the unanimity
surrounding medical research funding has been challenged by the issue of
embryonic stem cell research-an issue that firmly confronts the ethical
construct of biomedical research with the concepts of life and death,
health and healing. In this piece, I provide an overview of the political and
scientific history of the embryonic stem cell issue, evaluate the current
political landscape, and discuss the future of this research.
I. HISTORY AND SCIENCE
On November 6, 1998, a team of researchers led by Dr. James
Thomson at the University of Wisconsin published a paper outlining the
successful isolation of pluripotent stem cells from human embryos, thus
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thrusting embryonic stem cell research to the forefront of debate.1 As is
well known by now, embryonic stem cells are derived from the inner cell
mass of a blastocyst-stage (five to six days old) embryo. Although these
inner cells have lost the ability to form supporting tissues, they retain the
ability to develop into any cell type found in the body and are considered
pluripotent. Over time, and if allowed, they may multiply and differentiate
further, becoming committed to specific lineages. These pluripotent
embryonic stem cells, when properly isolated and cultured, appear to
contribute to all cell types found in the adult and seem to be capable of
indefinite self-renewal.2
It is also now known that there exist relatively undifferentiated and
self-renewing cells known as adult stem cells throughout the adult body-
cells that help repair tissues harmed by injury, disease, or natural cell
death. The most widely known and understood example of such a cell is
the hematopoietic stem cell, found in bone marrow and responsible for
the production of blood cells. Other promising cell types include neural
stem cells and mesenchymal stem cells. Reports have also appeared touting
the potential of stem cells from fat tissue, as well as those from umbilical
cord blood.3
Until recently, adult stem cells were considered rare and inflexible,
believed only to be able to form the cell types for the tissue in which they
were found. Moreover, most adult stem cells have not grown well in culture
and have remained difficult to obtain in significant quantities. However,
recent news reports suggest that adult stem cells may have more plastic
properties than previously believed, and the techniques for growing adult
stem cells are being improved. For example, on January 23, 2002, New
Scientist reported that researchers had discovered mulitpotent adult
progenitor cells in adult bone marrow. Such cells appear capable of
differentiating into all cell types and may avoid some of the difficulties
associated with embryonic stem cells. Moreover, adult stem cells from
human marrow have been expanded extensively in laboratories. While
adult stem cells may not be capable of indefinite self-renewal, they do not
also exhibit the tendency of embryonic stem cells to become malignant.
4
Ultimately, there remain many challenges and uncertainties surrounding
both adult and embryonic stem cells.
II. POTENTIAL APPLICATIONS OF EMBRYONIC AND ADULT STEM CELLS
Both human embryonic and adult stem cell research hold tremendous
potential for a wide range of uses, including clinical applications of cell-
based therapies for diabetes, Parkinson's disease, Alzheimer's disease,
leukemia, spinal cord injuries, and a number of other diseases and injuries.
11:1 (2001)
2
Yale Journal of Health Policy, Law, and Ethics, Vol. 2 [2002], Iss. 1, Art. 9
https://digitalcommons.law.yale.edu/yjhple/vol2/iss1/9
CASE STUDY-FRIST
This research may be useful in providing scientists with a better
understanding of the human cellular growth and differentiation process,
thus allowing researchers to seek out and attempt to treat or prevent the
causes of birth defects, genetic abnormalities, and diseases. The research
may also be useful in pharmaceutical development, allowing researchers to
grow large numbers of various cell types in order to test drug effectiveness
and toxicity.5
It is critical, however, that advocates not embellish the potential of
either embryonic or adult stem cell research for medical therapies. This
evolving science is still very young (the original Thomson discovery was
published only three years ago). Further basic research must be conducted
before we can hope to see clinical trials and possible treatments. In fact,
with the exception of hematopoietic stem cells that have been used for
many years in bone marrow transplantation, no other stem cells, neither
embryonic nor adult, have yet demonstrated therapeutic applications.
Some of the challenges remaining for both avenues of research
include: (1) learning the signals governing the differentiation of stem cells;
(2) overcoming the challenge of immune rejection in cell transplantation;
and (3) establishing consistent, effective methods to culture, isolate, and
grow the cells in a timely manner that is consistent with good
manufacturing processes.6 The bottom line is that treatments, if they will
be discovered, are likely several years away. Yet, the hope that they will
someday yield therapies for those suffering from disease is powerful.
III. THE IMPORTANCE OF FEDERALLY FUNDED RESEARCH
Our nation's unique combination of public and private funding for
scientific research is the envy of the world. It attracts the best researchers
and has led to an explosion of medical and scientific innovations that are
producing new treatments and hope for patients suffering from a wide
range of disease.7 Policymakers and the public are increasingly aware of the
great potential of biomedical research, and this awareness has spawned an
insatiable appetite for more and faster advances.
Because of this, Congress has worked during the past several years to
double federal funding for the National Institutes of Health (NIH). In fact,
the fiscal year 2003 budget proposed by President Bush completes this
process, increasing NIH funding from $13.6 billion in fiscal year 1998 to
$27.3 billion in fiscal year 2003. But to this point, many researchers have
been discouraged from entering this new field of embryonic stem cell
research because of the lack of federal funding. This is precisely why
federal funding is so critical. It is clear that federal involvement in
embryonic stem cell research will expedite scientific advancement by
3
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making the research available to scores of the nation's best and brightest
investigators, and improve research by ensuring that adult stem cell and
embryonic stem cell research are conducted along side each other.
Federal funding should also bring a much-needed level of ethical
safeguards and federal oversight to the field. To date, embryonic stem cell
research has taken place with no federal supervision or regulation. Reports
of researchers deriving embryonic stem cell lines from human embryos
created specifically for research have made this pressing need clear. The
continually evolving interaction between this promising but uncharted new
science with the ethical and moral considerations of life demands a strong,
comprehensive, publicly accountable oversight structure. It demands a
policy that is responsive on an ongoing basis to moral, ethical, and
scientific considerations. It is, therefore, up to policymakers to ensure that
this research is subject to the highest standards of public transparency and
effective regulation.
IV. THE INTERPLAY OF SCIENCE, ETHICS, AND PUBLIC POLICY
As the desire for new therapies and treatments grows, we must
recognize that science is not practiced in a vacuum. Moral and ethical
considerations cannot be ignored. With the ever-increasing pace of
progress have come new challenges of ethics and technologies that have, at
times, threatened the ability of public policy to respond. But, I deeply
believe that we, as legislators, have an obligation to do just that.
There are those who argue that "politics" should not impinge on
scientific process. I disagree. It is the role of politics to ensure that taxpayer
money is used in a manner that is responsive to public interest and is
acceptable to society. It is the role of politics to ask the question posed by
the Washington Post several years ago: "Is there a line that should not be
crossed, even for scientific or other gain, and if so, where is it?"8 In fact,
politics should and does have an important role in deciding what research
is not only scientifically promising but also socially acceptable.
As a transplant surgeon, I have confionted many life-and-death
decisions. I have performed hundreds of organ and tissue transplants and
experienced the ethical dilemmas involved in end-of-life care. Having
practiced in the early days of heart and lung transplantation, I have
witnessed the powerful impact of medical progress on each of my patients.
Moreover, I have seen firsthand the impact that medical and technological
progress have had on reshaping legal and ethical criteria, as well as how
ethics has shaped the practice of medicine.
As a surgeon, I frequently removed a heart from a brain-dead
11:1 (2001)
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individual and placed that heart into another patient who would have
otherwise died. That required a determination of when brain death
occurred-a routine process today that was very controversial when it was
first developed just three decades ago.
Historically, death was not particularly difficult to determine or define.
Generally, all vital systems of the body-respiratory, neurological, and
circulatory-would fail at the same time, and none of these functions
could be prolonged without the maintenance of the others. However,
technological advances in life support, particularly the development of
ventilators, have made it possible to keep some bodily systems functioning
long after others have ceased.
These technical advances opened up the possibility of organ
transplants and also created a need for the development of a neurological
standard for determining when death occurs. Only after death has been
determined is it appropriate to consider organ donation. On this basis,
there is now broad public support for organ donation. It must be
remembered, however, that the cohesive interplay of science, ethics, and
policy did not come easily.
A similar dilemma now confronts us in the field of embryonic stem cell
research. The question is much like that faced in the early days of organ
transplantation: Do we remove organs and tissue for transplantation and
research from an individual who is brain dead, but whose other organs
continue to live and function normally? The question today is whether to
fund research using stem cells derived from blastocysts that could, if
implanted, become a fetus, but that will otherwise be discarded. I believe
the provision of funding for such research is the proper course, but only
under the strictest of regulations to ensure a clear separation of the
decisions to discard excess embryos, donate them for adoption, or donate
them for research, in an approach consistent with the precedent of organ
donation.
V. THE PRESIDENT'S DECISION
In the first half of 2001, the question of federal funding for embryonic
stem cell research reached new heights of attention as pressure mounted
for President Bush to determine whether to implement the NIH
Guidelines on embryonic stem cell research, promulgated under the
previous administration. With growing public interest, members of
Congress were also forced to confront these issues. As the only physician in
the U.S. Senate, I felt particularly compelled to study the issue and make
my position clear. On July 18, I announced a comprehensive framework
for the support of embryonic stem cell research. 9 This position, based on
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the following ten points, would allow stem cell research to move forward in
a manner respectful of both the moral significance of human embryos and
the potential of stem cell research to improve health: (1) a ban on the
creation of embryos for research purposes; (2) the continuation of the
present ban on federal funding of the derivation of embryonic stem cells;
(3) a ban on all human cloning; (4) an increase in adult stem cell research
funding; (5) funding for embryonic stem cell research only from
blastocysts that would otherwise be discarded; (6) a rigorous informed
consent process; (7) a limited number of stem cell lines; (8) a strong
public research oversight system; (9) ongoing, independent scientific and
ethical review; and (10) strengthened and harmonized fetal tissue research
restrictions.
On August 9, 2001, President Bush announced a decision that may
dramatically alter the course of biomedical research. After a lengthy
process of thorough study, consultation, and reflection, the President
decided to permit the NIH to fund research using embryonic stem cell
lines already in existence on that date.1° His decision means that, for the
first time, the nation's premier federally supported scientists will be able to
perform research using embryonic stem cells. It means that, for the first
time, this research will be conducted by a broad number of scientists-and
not merely by those using private funds. Because the President's focus was
on the use of existing cell lines, some of the protective criteria I detailed
are not necessary-for example, as rigorous an informed consent process
since the cell lines already exist. But the President's position expressly or
implicitly endorses a number of my criteria, such as a ban on the creation
of embryos for research, a ban on human cloning, and a ban on federal
funding for the derivation of embryonic stem cells. These standards, in
particular, and the President's decision ensure a strong and cohesive moral
construct, in general, that will become even more critical as science and
research in these areas progress.
As attention has focused on this research in the last year, a great deal
has been learned about both adult and embryonic stem cells. During the
President's deliberations, the NIH determined the existence of more than
sixty embryonic stem cell lines worldwide-considerably more than
previously thought." There are presently more than seventy lines in the
NIH registry. But this process has also reminded us how little is known
about this science and has driven home the fact that there is still far to go.
In the wake of the President's decision, some have challenged the
viability of all those cell lines. Others have argued that these cells lines are
not enough to meet research needs.1 2 Still others are disappointed that the
President decided to allow the use of federal funds for research on any
11:1 (2001)
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embryonic stem cells. 3
The President's decision means that embryonic stem cell research will
expand dramatically. This research may open the door to therapies and
cures beyond our imaginations. For the first time, federal funds will be
used to better understand the earliest stages of human life, and the
existence of a public embryonic stem cell registry should ensure that
research and discoveries are shared broadly and rapidly.
We should commend the NIH for taking important steps to move this
research forward through the establishment of a stem cell registry where
researchers around the world, as well as the general public, can access
information about embryonic stem cell lines available for research. This
registry has already been important in bringing a new level of public
transparency to the research and expanding our knowledge about the
global state of the science. Because of the NIH's work in establishing the
registry, we know the location of more than seventy embryonic stem cell
lines that are currently available. Moreover, the registry includes
information on how they were derived, what their basic characteristics are,
and how to contact their owners.
The registry represents a commitment by the NIH and the President to
facilitate scientists' access to embryonic stem cells. Moreover, the NIH has
built upon the registry by negotiating a Memorandum of Understanding
(MOU) with the Wisconsin Alumni Research Foundation, which holds
patent rights to the cell lines developed by Thomson. The MOU enables
the NIH and NIH-funded investigators to access these cell lines under
minimal conditions.14 Hopefully, this agreement will serve as a model for
such arrangements in the future.
But this research carries great moral as well as great medical danger,
namely the potential to inflict harm. Because we have barely begun to
understand its capacities, pioneers in the field must approach this research
with the awe and respect it deserves. We must move forward with caution
and restraint, remembering that it is untried, untested, and unproven. We
must proceed within the context of a fully transparent, carefully regulated
framework that ensures respect for the potential of this research and for
the moral significance of the human embryo.
5
Much of the public discussion and analysis of the President's decision
has centered on whether his stipulations are sufficient for the success of
this research. Issues such as autoimmune rejection and cell line diversity
have been raised as potential obstacles. 6 While the fact that existing cell
lines have been cultured and grown on mouse feeder cells has concerned
some, the Food and Drug Administration (FDA) has said that this is not a
barrier to this research. In fact, there are presently several active
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Investigations for New Drugs for xenotransplantation products presently in
clinical trials. 7
While the concerns about the potential restraints of research limited
to existing cell lines may one day prove valid, they will not prohibit the
research from moving forward. Research knowledge will expand
exponentially as we move beyond the relatively few cell lines isolated at the
University of Wisconsin and begin to use the more than seventy lines
available worldwide. 8 Moreover, the NIH currently spends more than $250
million per year on stem cell research-a figure that will continue to rise in
the coming years as overall NIH funding continues to expand.' 9 Ultimately,
far more research must be done before we know the answers to the
concerns-but, it is now up to the researchers to move forward. Should
there come a time that a real obstacle to the continuation and success of
embryonic stem cell research emerges, Congress might look to alleviate
such a situation in a manner consistent with the rigorous standards that I
have outlined. But there is much work to be done before we will know
whether this is necessary. This is, after all, a new and evolving science.
The President has also taken a crucial step towards the long-term
success and viability of embryonic stem cell research by recognizing the
need for continuing moral and ethical oversight of this and other pressing
issues in the fields of bioethics and medical advancement. The new
Council on Bioethics, to be led by Dr. Leon Kass of the University of
Chicago, will play an integral role in monitoring and advising the nation
about the moral and ethical considerations that may be raised by a wide
range of scientific breakthroughs.
VI. THE FUTURE OF STEM CELL RESEARCH
One critical aspect of the embryonic stem cell framework that was
perhaps overlooked, or afforded less attention, when I announced my
position in July 2001, was cloning. It is imperative that federal legislation
be enacted to ban all human cloning. There are three primary reasons I
believe a ban is necessary. First, the technique by which cloning is done,
somatic cell nuclear transfer, remains highly inefficient and risky to the
embryo-with very high failure, death, and mutation rates. Second,
allowing human cloning opens the door to the exploitation of women as
egg donors by creating a market for already in-demand oocytes. This would
lead to often poor minority women undergoing risky superovulation
treatments because of the high financial incentives involved. Finally, there
is broad agreement that the creation of embryos solely for research is
unethical and should be prohibited.
In addition, science has progressed to the point that we know a human
11:l1(2001)
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cloning ban will not derail stem cell research. In 1998, when I authored
one of the first pieces of federal legislation prohibiting cloning, concerns
existed that a cloning prohibition would impede embryonic stem cell
research. However, subsequent advances in our knowledge of the
successful development of embryonic stem cell lines at the University of
Wisconsin and the identification of more than seventy such existing cell
lines to date have made clear that banning cloning will not materially
curtail embryonic stem cell research. Science has advanced to the stage
where we now know more definitively, not only that embryonic stem cell
research will not be hindered, but also that such research can, and will,
proceed aggressively without the use of human cloning.
We will have to wait several years to know whether embryonic stem cell
research may yield practical therapies. In the meantime, we should move
aggressively forward in implementing the President's policy and to
examine its progress closely over the coming months and years. As the
research moves forward, ongoing congressional and scientific oversight will
be critical to reevaluating the progress and needs of this research. Just as
important, ongoing discussion among scientists, policymakers, ethicists,
religious leaders, and the American people will be critical to maintaining
the proper balance between science and ethics and to ensuring the
ultimate success of our biomedical research endeavors.
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